$20.29
-0.63[-3.01%]
At close: May 17
$20.29
0[0.00%]
After Hours: 4:00PM EDT
Syndax Pharmaceuticals
(NASDAQ:SNDX)Syndax Pharmaceuticals Stock (NASDAQ:SNDX), Analyst Ratings, Price Targets, Predictions
Syndax Pharmaceuticals Inc has a consensus price target of $33.86, established from looking at the 44 latest analyst ratings. The last 3 analyst ratings were released from Citigroup, Stifel, and HC Wainwright & Co. on May 9, 2024. With an average price target of $37 between Citigroup, Stifel, and HC Wainwright & Co., there's an implied 82.36% upside for Syndax Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
Stifel
HC Wainwright & Co.
JP Morgan
Scotiabank
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Syndax Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/09/2024 | Buy Now | 47.86% | Citigroup | Yigal Nochomovitz | $32 → $30 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 97.14% | Stifel | Bradley Canino | $39 → $40 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 102.07% | HC Wainwright & Co. | Edward White | → $41 | Reiterates | Buy → Buy | Get Alert |
| 04/26/2024 | Buy Now | 102.07% | HC Wainwright & Co. | Edward White | → $41 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2024 | Buy Now | 102.07% | HC Wainwright & Co. | Edward White | → $41 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 102.07% | HC Wainwright & Co. | Edward White | $41 → $41 | Maintains | Buy | Get Alert |
| 03/20/2024 | Buy Now | 67.57% | JP Morgan | Anupam Rama | $31 → $34 | Maintains | Overweight | Get Alert |
| 02/28/2024 | Buy Now | 102.07% | HC Wainwright & Co. | Edward White | → $41 | Reiterates | Buy → Buy | Get Alert |
| 01/31/2024 | Buy Now | 13.36% | Scotiabank | George Farmer | $36 → $23 | Downgrade | Sector Outperform → Sector Perform | Get Alert |
| 01/02/2024 | Buy Now | 102.07% | HC Wainwright & Co. | Edward White | → $41 | Reiterates | Buy → Buy | Get Alert |
| 12/22/2023 | Buy Now | 102.07% | HC Wainwright & Co. | Edward White | $42 → $41 | Maintains | Buy | Get Alert |
| 12/22/2023 | Buy Now | 121.78% | Mizuho | Mara Goldstein | → $45 | Initiates | → Buy | Get Alert |
| 10/26/2023 | Buy Now | 77.43% | Stifel | Bradley Canino | $38 → $36 | Maintains | Buy | Get Alert |
| 10/25/2023 | Buy Now | 42.93% | B of A Securities | Jason Zemansky | → $29 | Initiates | → Buy | Get Alert |
| 10/17/2023 | Buy Now | 87.28% | JP Morgan | Anupam Rama | $36 → $38 | Maintains | Overweight | Get Alert |
| 10/11/2023 | Buy Now | 47.86% | Goldman Sachs | Chris Shibutani | → $30 | Initiates | → Buy | Get Alert |
| 10/02/2023 | Buy Now | 107% | HC Wainwright & Co. | Edward White | $38 → $42 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2023 | Buy Now | 62.64% | JP Morgan | Anupam Rama | $36 → $33 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 87.28% | HC Wainwright & Co. | Edward White | → $38 | Reiterates | → Buy | Get Alert |
| 07/27/2023 | Buy Now | 92.21% | Scotiabank | George Farmer | → $39 | Initiates | → Sector Outperform | Get Alert |
| 07/26/2023 | Buy Now | 72.5% | Citigroup | Yigal Nochomovitz | $31 → $35 | Maintains | Buy | Get Alert |
| 07/26/2023 | Buy Now | 67.57% | Barclays | Peter Lawson | $31 → $34 | Maintains | Overweight | Get Alert |
| 07/25/2023 | Buy Now | 107% | Guggenheim | Michael Schmidt | $40 → $42 | Maintains | Buy | Get Alert |
| 07/25/2023 | Buy Now | 77.43% | B. Riley Securities | Kalpit Patel | $34 → $36 | Maintains | Buy | Get Alert |
| 07/24/2023 | Buy Now | 87.28% | HC Wainwright & Co. | Edward White | $36 → $38 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 97.14% | Guggenheim | Michael Schmidt | → $40 | Initiates | → Buy | Get Alert |
| 06/26/2023 | Buy Now | 72.5% | BTIG | Justin Zelin | $34 → $35 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 52.78% | Citigroup | Yigal Nochomovitz | $32 → $31 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 77.43% | HC Wainwright & Co. | Edward White | $33 → $36 | Maintains | Buy | Get Alert |
| 03/07/2023 | Buy Now | 77.43% | JP Morgan | Anupam Rama | $41 → $36 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Syndax Pharmaceuticals (SNDX)?
The latest price target for Syndax Pharmaceuticals (NASDAQ: SNDX) was reported by Citigroup on May 9, 2024. The analyst firm set a price target for $30.00 expecting SNDX to rise to within 12 months (a possible 47.86% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Syndax Pharmaceuticals (SNDX)?
The latest analyst rating for Syndax Pharmaceuticals (NASDAQ: SNDX) was provided by Citigroup, and Syndax Pharmaceuticals maintained their buy rating.
When was the last upgrade for Syndax Pharmaceuticals (SNDX)?
There is no last upgrade for Syndax Pharmaceuticals.
When was the last downgrade for Syndax Pharmaceuticals (SNDX)?
The last downgrade for Syndax Pharmaceuticals Inc happened on January 31, 2024 when Scotiabank changed their price target from $36 to $23 for Syndax Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Syndax Pharmaceuticals (SNDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Syndax Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Syndax Pharmaceuticals was filed on May 9, 2024 so you should expect the next rating to be made available sometime around May 9, 2025.
Is the Analyst Rating Syndax Pharmaceuticals (SNDX) correct?
While ratings are subjective and will change, the latest Syndax Pharmaceuticals (SNDX) rating was a maintained with a price target of $32.00 to $30.00. The current price Syndax Pharmaceuticals (SNDX) is trading at is $20.29, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.